From FDA Approves First Drug for Exelixis of South San Francisco:

Exelixis Logo—

Exelixis (NASDAQ: EXEL) is a South San Francisco biotechnology company developing drugs for thyroid cancer, prostate cancer, and other conditions.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

From Our Editors · Special Report
Xcelerating Life Sciences San Francisco: Special Report
The AI, Big Data, and R&D Boom

Sponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
CMC in Drug Development and Life Cycle Management
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!